I think they said no cost in the first year, as it is covered under project implementation cost which will hit capex. After that, annual running costs would be significantly lower (comparatively) but was to be disclosed later. Hopefully in the next earnings call.

Quarterly sales down by more than 50%. Management did not comment on Q-to-Q basis. But looks postive for long term. The price may consolidate at CMP until the next quarter results.
Disclaimer:i am invested in this co.

Alembic Pharma reported muted nos, with sales growing by 8% and EPS largely being flat. They have started launching injectable, onco and derma products in US. Their non-US market is doing very well. Concall notes below.

FY24Q2

• 12MW solar plant commissioned in October 2023, ROI of 18-20%
• Animal health business has now scaled to 98 cr. quarterly run rate (32% growth). Business has grown at 18% CAGR in last 5 years. Established a new division with 350 people. Margins are a tad lower than corporate level profitability
• New facilities contributed 60-70 cr. to quarterly expenses
• Have seen very good pickup in oncology product in US, injectable product has also seen good market share gains without much price erosion
• Out of 20 planned US launched, 10-12 will be OSDs and remaining will be ophthalmic injectable and derma products
• US filing rate has reduced from 20-25 products to 15 now (will reduce R&D spends)
• Will launch 10+ products in US in H2

Disclosure: Invested (position size here, bought shares in last-30 days)

Things like these are non events. Unless something truly serious is found. IT proceedings take a long time and the assessees often go for multiple appeals. There should be no medium term impact on financials and operations.